

University of Groningen

Automated causal inference in application to randomized controlled clinical trials

Wu, Ji Q.; Horeweg, Nanda; de Bruyn, Marco; Nout, Remi A.; Jürgenliemk-Schulz, Ina M.; Lutgens, Ludy C.H.W.; Jobsen, Jan J.; van der Steen-Banasik, Elzbieta M.; Nijman, Hans W.; Smit, Vincent T.H.B.M.

Published in:
Nature Machine Intelligence

DOI:
[10.1038/s42256-022-00470-y](https://doi.org/10.1038/s42256-022-00470-y)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Wu, J. Q., Horeweg, N., de Bruyn, M., Nout, R. A., Jürgenliemk-Schulz, I. M., Lutgens, L. C. H. W., Jobsen, J. J., van der Steen-Banasik, E. M., Nijman, H. W., Smit, V. T. H. B. M., Bosse, T., Creutzberg, C. L., & Koelzer, V. H. (2022). Automated causal inference in application to randomized controlled clinical trials. *Nature Machine Intelligence*, 4, 436–444. <https://doi.org/10.1038/s42256-022-00470-y>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



OPEN

Automated causal inference in application to randomized controlled clinical trials

Ji Q. Wu ¹✉, Nanda Horeweg², Marco de Bruyn ³, Remi A. Nout^{2,9}, Ina M. Jürgenliemk-Schulz⁴, Ludy C. H. W. Lutgens⁵, Jan J. Jobsen ^{6,10}, Elzbieta M. van der Steen-Banasik⁷, Hans W. Nijman³, Vincent T. H. B. M. Smit⁸, Tjalling Bosse⁸, Carien L. Creutzberg ² and Viktor H. Koelzer ¹✉

Randomized controlled trials (RCTs) are considered the gold standard for testing causal hypotheses in the clinical domain; however, the investigation of prognostic variables of patient outcome in a hypothesized cause–effect route is not feasible using standard statistical methods. Here we propose a new automated causal inference method (AutoCI) built on the invariant causal prediction (ICP) framework for the causal reinterpretation of clinical trial data. Compared with existing methods, we show that the proposed AutoCI allows one to clearly determine the causal variables of two real-world RCTs of patients with endometrial cancer with mature outcome and extensive clinicopathological and molecular data. This is achieved via suppressing the causal probability of non-causal variables by a wide margin. In ablation studies, we further demonstrate that the assignment of causal probabilities by AutoCI remains consistent in the presence of confounders. In conclusion, these results confirm the robustness and feasibility of AutoCI for future applications in real-world clinical analysis.

Many clinical studies are driven by the research questions that are statistical at first glance but causal by nature¹. For instance², how safe and efficient is a vaccine against viral infection? How are clinicopathological variables³ related to cancer patient survival? From the causal perspective, the common ground of these problems starts with determining the causal variables of the outcome of interest. In clinical medicine, randomized controlled trials (RCTs) are considered to be the gold standard to investigate cause–effect relationships⁴. In a prototypical RCT, a participant is randomly assigned to the experimental or control arm and the outcome of interest is observed. In the context of causal inference, such a randomization can be modelled with do-intervention⁵.

In this Article, we develop a new automated causal inference method (AutoCI) and apply this to two large-scale, practice-changing RCTs of patients with endometrial carcinoma conducted in the Netherlands from 1990–1997 (PORTEC 1; refs. ^{6,7}) and 2002–2006 (PORTEC 2; refs. ^{8,9}), with full clinicopathological datasets and mature outcome data. Endometrial carcinoma is the most common type of gynaecological cancer for women in developed countries¹⁰. The majority of women that are diagnosed with early stage endometrial cancer (EC) have a favourable prognosis and are treated with surgery¹¹. Approximately 15–20% of patients have an unfavourable prognosis with a high risk of distant metastasis¹¹. For those patients, different adjuvant therapies such as vaginal brachytherapy, external beam radiotherapy and chemoradiation are recommended on the basis of their risk group¹². The two trials (PORTEC 1 and 2) used in this study made a key contribution to clinical practice by investigating how these therapies impact the risk of recurrence rates and survival^{6,8}. According to the latest ESGO/ESTRO/ESP guidelines¹²

for the management of patients with endometrial carcinoma, the risk classification is based on a series of clinical and pathological variables such as tumour grading (Grade), lymphovascular space invasion (LVSI), myometrial invasion and so on, as well as molecular variables including—but not limited to—polymerase epsilon mutant EC (POLEmut), mismatch repair deficient (MMRd) EC, p53 abnormal EC (p53abn) and EC with no specific molecular profile (NSMP)¹². Correlative statistical methods were used in a recent study³ to investigate the hazardous relevance of these variables to EC recurrence. There is strong evidence to suggest that these variables impact EC recurrence, but a systematic investigation to support this understanding from a modern causal inference perspective has not been performed.

Causal inference addresses the determination of cause–effect relationships from data^{13–16}. When given either observational data or the inclusion of additional interventional data, clinical studies aim to either (1) quantify the causal effect of a treatment given the outcome¹³ or (2) infer the underlying causal structure of relationships between patient and treatment characteristics and relevant outcomes^{5,17}.

The former can be well formulated as the difference between the outcome expectations conditioned on different treatments (average causal effect)¹³. A wide range of studies have built on this methodology, including—but not limited to—target trial specification¹⁸, target trial emulation^{19,20} and extending inferences from randomized trials to new target populations²¹.

In comparison to the causal effect identification, we refer to (2) as (causal) structure identification⁵. The goal of structure identification is often to learn the entire causal structure, that is, a directed

¹Department of Pathology and Molecular Pathology, University Hospital, University of Zurich, Zurich, Switzerland. ²Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands. ³Department of Obstetrics and Gynecology, University of Groningen, University Medical Center, Groningen, Groningen, the Netherlands. ⁴Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.

⁵Maastricht Radiation Oncology Clinic, Maastricht, the Netherlands. ⁶Department of Radiotherapy, Medisch Spectrum Twente, Enschede, the Netherlands.

⁷Radiotherapiegroep, Arnhem, the Netherlands. ⁸Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. ⁹Present address:

Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands. ¹⁰Present address:

Department of Clinical Epidemiology, Medisch Spectrum Twente, Enschede, the Netherlands. ✉e-mail: Jiqing.Wu@usz.ch; Viktor.Koelzer@usz.ch

Table 1 | The comparison of causal variable determination for the PORTEC dataset among ICP, NICP and the proposed method

	ICP	NICP	Proposed (warm-up)	Proposed (complete)
Causal determination of P				
Pathological				
Myometrial invasion	No	Yes	55.33%	52.13%
Grade	No	Yes	62.72%	60.71%
LVSI	No	Yes	60.68%	59.41%
Sanity check				
Tissue area	No	Yes	49.31%	35.96%
Patient ID	No	Yes	50.93%	20.61%
Causal determination of PM				
Pathological				
Myometrial invasion	No	Yes	54.62%	53.16%
Grade	No	Yes	60.44%	60.42%
LVSI	No	Yes	62.13%	60.87%
Molecular				
L1CAM	No	Yes	60.27%	60.43%
POLEmut	No	Yes	49.91%	50.02%
MMRd	No	Yes	49.20%	49.25%
p53abn	No	Yes	64.67%	63.92%
Sanity check				
Tissue area	No	Yes	49.77%	24.94%
Patient ID	No	Yes	48.98%	17.48%
Causal determination of PMI				
Pathological				
Myometrial invasion	No	Yes	55.22%	53.84%
Grade	No	Yes	59.39%	59.74%
LVSI	No	Yes	61.88%	60.56%
Molecular				
L1CAM	No	Yes	59.91%	59.92%
POLEmut	No	Yes	50.08%	50.46%
MMRd	No	Yes	49.10%	49.40%
p53abn	No	Yes	63.82%	62.91%
Immune				
CD8+ cell density	No	Yes	56.33%	56.14%
Sanity check				
Tissue area	No	Yes	49.58%	21.12%
Patient ID	No	Yes	49.18%	22.89%

The causal variable determination of pathological variables (P), pathological and molecular variables (PM), and pathological, molecular and immune variables (PMI). Here, we report yes (causal) or no (non-causal) for ICPs and causal probability for the proposed AutoCI. The proposed (warm-up) refers to steps 1 and 2 of the pseudo code in Fig. 1.

acyclic graph composed of nodes and edges that connect nodes; however, this is generally a non-deterministic polynomial-time hard problem^{16,22}. To learn the cause–effect relations without inferring the entire causal structure, invariant causal prediction (ICP)²³ was proposed to determine the set of causal variables given an outcome variable. Under the ICP framework, we use the random variable concept (informally, a function that assigns a set of possible samples to a measurable quantity) and define causal variable as follows (see Supplementary Table 1 for summarized terminologies used in the paper).

Definition 1. Assume there exists a set of environments $u \in U$, given a collection of random variables $\mathbf{X} = (X_1, X_2, \dots, X_n)$ and an outcome variable Y , if $\mathbf{X}_{S^*} = (X_{S_1^*}, \dots, X_{S_j^*})$ exists with indices $S^* \subseteq \{1, \dots, n\}$ such that

$$Y = f^*(\mathbf{X}_{S^*}^u) + \delta^u \quad \forall u \in U, \text{ where } f^*: \mathbb{R}^{|S^*|} \mapsto \mathbb{R}. \quad (1)$$

$$\delta^u \text{ are } \begin{cases} \text{identically distributed (i.d.)} & \text{if } \exists \text{ hidden confounders} \\ \text{i.d. and } \delta^u \perp \mathbf{X}_{S^*}^u & \text{else} \end{cases} \quad (2)$$

Then \mathbf{X}_{S^*} are the plausible causal variables (under U). Here, $\mathbf{X}_{S^*}^u = (X_{S_1^*}^u, \dots, X_{S_j^*}^u)$ are the corresponding random variables to $\mathbf{X}_{S^*} = (X_{S_1^*}, \dots, X_{S_j^*})$ created under the environment u . For example, the (experimental) environment u can arise via do-intervention¹⁷ ($do(X_0 := c)$) on X_0 , then X_0^u only samples the fixed value c . It is worth noting that the cause–effect relation f^* in equation (1) stays invariant and independent of U . Next we introduce the definition of identifiable causal variables.

Definition 2. Following the specification of U , $\mathbf{X} = (X_1, X_2, \dots, X_n)$ and Y in Definition 1, if a $\mathbf{X}_{\bar{S}} = (X_{\bar{S}_1}, \dots, X_{\bar{S}_j})$ exists with indices $\bar{S} \subseteq \{1, \dots, n\}$ such that

$$\bar{S} := \bigcap \{S \subseteq \{1, \dots, n\} \mid \mathbf{X}_S \text{ are plausible causal variables}\}, \quad (3)$$

then $\mathbf{X}_{\bar{S}}$ are the identifiable causal variables (under U), as they are referred to henceforth.

Vanilla ICP²³ was initially presented and verified on linear cause–effect relations. Heinze-Deml and co-workers²⁴ next defined u as a random variable that is neither the descendant nor the parent of Y , and conducted multiple conditional independence tests on nonlinear cause–effect settings (NICP). Gamella and Heinze-Deml²⁵ recently suggested investigating the stable set of variables instead, which is a relaxation of the set of identifiable causal variables (AICP). This progress in ICP has opened unprecedented paths to interpret complex datasets, especially those collected from RCTs. Finding which variables determine whether a treatment works or whether a patient will have a recurrence using ICP methods has great scientific potential. In application to the clinical domain, data interpretation by causal inference methods could improve our understanding of disease and aid in the design of new experiments and clinical trials; however, non-negligible efforts are required to adopt the existing ICPs to the clinical domain. This is due to: (1) the complexity and multitude of variables that are considered relevant for treatment outcomes including patient level characteristics (patient demographics, text data from clinical records), information derived from images (radiology, pathology) and molecular data (genomic sequencing); and (2) the incompatibility between the error-tolerant implementation for the simulated dataset and safe-critical application relevant for medical decisions. Candidate ICP methods therefore need to be robust against noise and need to provide meaningful outputs that can be related to clinical risk in order to inform patient stratification.

Results

Clinical variables overview. The PORTEC 1 and 2 trials^{6,8} recruited 714 (since 1990–1997) and 427 (since 2000–2006) patients with early stage endometrial carcinoma respectively; 305 cases from PORTEC 1 (42.7%) and 335 cases from PORTEC 2 (78.5%) with complete clinicopathological datasets were aligned and used in the experiments. Clinicopathologic characteristics of these subgroups were similar to the original trial populations (less than or equal to 17.3% absolute difference in frequency of any variable). Importantly, there was no substantial difference in the variable of interest (mean and five-year recurrence free survival (RFS)) for causal variable




Fig. 1 | The overall model illustration and performance of the proposed AutoCI. Top: an illustrative scheme of the proposed AutoCI. In the syntax (top left), the type T includes atomic type (ATM), function type (FUC) and abstract data type (ADT), the program prg contains neural network (NN), function composition (COMP), concatenation (CAT), filter (FILTER), predicate (PRED) and so on. In the causal differentiable learning, causal prob. indicates causal probability. The outcome variable RFS means recurrence free survival. Bottom left: the sampled numbers of type-safe functions versus generic functions. Here the size is the maximum amount of nn and PRED functions allowed during the program synthesis. Bottom middle: the learning curve of the JS for top-four type-safe functions achieved in the case with pathological, molecular and immune variables. Bottom right: the running time of determining the causal variables for P, PM and PMI. Here the proposed AutoCI utilizes the function $\text{COMP}(\text{NN}, \text{CAT}(\text{FILTER}(\text{PRED})))$.

identification between the excluded and included patient datasets, supporting that our analysis is representative of the overall study population (Supplementary Fig. 1 and Supplementary Tables 2 and 3). Considering PORTEC 1 and 2 as the two experimental environments, we aimed to determine the causal pathological, molecular and immune-related variables of EC recurrence status.

Pathological variables. Pathological criteria tumour grading (Grade)^{26,27}, LVSI²⁸ and myometrial invasion^{26,27} are examined in the study, all of which are important indicators for an elevated risk of EC recurrence (see also ref.¹²). All variables were reevaluated on formalin-fixed paraffin-embedded tumour material by specialized gynecopathologists to guarantee variable consistency for the two environments (trials).

Molecular variables. The molecular classification of EC distinguishes four subtypes with validated prognostic impact: (1) ultra-mutated EC with DNA-polymerase epsilon exonuclease domain mutations (POLEmut), with an excellent prognosis; (2) hypermutated EC with MMRd, with an intermediate prognosis; (3) copy-number-high EC with frequent TP53 mutations (p53abn), with an unfavourable prognosis; and (4) copy-number-low EC without an NSMP, with an intermediate prognosis^{27,29}. Pathogenic POLE mutations were detected by next-generation sequencing of POLE hotspot exons³⁰. Mismatch repair deficient (MMRd) EC and p53 status were determined by immunohistochemistry³¹. Cases with more than one classifying feature were classified according to the dominant molecular feature on the basis of pathogenicity³². Over-expression of L1CAM by tumour cells was assessed by immunohistochemistry using a

cut-off of $\geq 10\%$ for positivity, and is associated with an increased risk of metastasis and death^{33,34}.

Immune variable. (Intraepithelial) CD8+ T-cell infiltration is an independent favourable prognostic indicator in early stage EC³. To quantify CD8+ T-cell infiltration in tissue samples of the PORTEC 1 and 2 trials, we compute CD8+ cell density derived from tissue microarrays by immunohistochemistry and image analysis^{3,35}. Specifically, tissue microarrays capture cancer tissue samples from each patient in a highly standardized manner, allowing for the highly accurate evaluation of tumour and microenvironment-related factors in cancer samples for investigation with clinical outcomes³⁶.

Based on existing domain knowledge and biological understanding^{3,29,31,37-39}, we consider the pathological (P), molecular (M) and immune (I) variables to be the proxies of causal variables (S_{prox}) (see Supplementary Table 3 for more characteristics details).

Sanity-check variables. To investigate the robustness of the causal inference models, we intentionally include a randomized number as the Patient ID and the vital tissue area of each tissue microarray core (where the tissue area is the sum of randomly sampled tumour and stroma areas from each case) in our subsequent analysis as non-causal variables. Based on prior domain knowledge, the two variables should not be causally related to cancer outcomes. The inclusion of these two non-causal variables thus serves as an important benchmark for comparison of the methods presented in this study. Importantly, as the two variables are expected not to impact clinical outcome and we attempt to verify that they do not impact




Fig. 2 | The learning performance and time of the optimal type-safe $f = \text{COMP}(\text{NN}, \text{CAT}(\text{FILTER}(\text{PRED})))$ on toy datasets. Left: the learning curve of the JS for top-four type-safe functions (finite sample setting). Middle: the learning curve of the JS for top-four type-safe functions (ABCD setting). Right: the running time of the compared methods for the finite sample and ABCD settings. Here the proposed AutoCI utilizes the function $\text{COMP}(\text{NN}, \text{CAT}(\text{FILTER}(\text{PRED})))$.

the outcome, this strategy can also be considered as a typical use case of negative control⁴⁰ in RCT studies.

PORTEC experiments overview. As presented in Fig. 1 (top), our proposed AutoCI is composed of two key components: (1) a program synthesis language that searches the type-safe function candidates automatically, and (2) a novel causal differentiable learning scheme that determines the causal variables. In the following we first present the experimental results with emphasis on the individual components (1) and (2). We then demonstrate the overall performance on the main and ablation studies for the complete AutoCI method, confirming that the integration of program synthesis with a causal differentiable learning scheme is a critical step towards automated causal inference for clinical applications.

Automated type-safe function search. Type-safe functions are favourable candidates to strengthen the security and reliability of critical software applications⁴¹. However, the manual verification of type-safe properties can be cumbersome, especially when examining thousands of function candidates. Figure 1 (bottom left) shows that the AutoCI can efficiently filter out a subset of promising type-safe differentiable functions (see also similar results in ref.⁴²), and this can be accomplished in a short period of time: 42.26 s, 118.56 s, 119.44 s for size = {3, 4, 5}. By automatically excluding a large amount of generic functions that are not type-safe, it can greatly improve the development efficiency and algorithm safety compared with manual function design. After obtaining the type-safe candidates, we execute the causal differentiable learning scheme (Fig. 1, top) on the candidates and determine the set of predicted causal variables S_{PRED} . Here we utilize the Jaccard similarity (JS)²⁵ as a key metric to measure the prediction accuracy,

$$\text{JS}(S_{\text{pred}}, S_{\text{prox}}) = \frac{|S_{\text{pred}} \cap S_{\text{prox}}|}{|S_{\text{pred}} \cup S_{\text{prox}}|} \quad (4)$$

Figure 1 (bottom middle) demonstrates the JS accuracy with the growing epochs for the top-four type-safe candidates (see also Supplementary Table 4). We conclude that the function $f = \text{COMP}(\text{NN}, \text{CAT}(\text{FILTER}(\text{PRED}))))$ achieves the optimal JS score (for example, $91.9 \pm 0.06\%$) and thus is used as the default function for further analysis. As pointed out in Valkov et al.⁴², HOUDINI allows us to transfer high-level modules across learning tasks. More specifically, the type-safe candidates discovered via the search algorithm are agnostic of disease-specific features for hazard analysis.

Independent of the hazard analysis conducted for cancer studies, these type-safe candidates can therefore be re-used and fine-tuned to perform causal variable identification given data on the survival outcome for each patient. Depending on the JS score achieved by the candidates we determine the optimal learned type-safe model. As a result, the proposed AutoCI approach can pave the way towards an efficient causal analysis for many of the real-world cancer studies.

Determining causal variables with clear differentiation. We compare the AutoCI with the state-of-the-art ICP methods, ICP and NICP. Although competitive results are achieved by AICP on the toy experiments, AICP requires the regeneration of additional interventional data in each learning step. Such a learning scheme is incompatible to the real-world RCTs setting, hence AICP is not applicable to the PORTEC experiments. As ICP and NICP explicitly accept or reject the variable of interest, we report yes or no in Table 1. For the proposed AutoCI, we report the mean of the causal probabilities for each variable. Overall, the proposed AutoCI outperforms the ICP and NICP in terms of differentiating causal and non-causal variables ($\geq 50\%$ versus $< 25\%$ for PMI), demonstrating its advantages over the SOTA methods by a clear margin (Table 1). When examining the individual variables of interest, we can see that ICP fails to determine the proxy variables to be the causal ones, whereas for NICP all of the variables—including the sanity check ones—are considered to be causal. These results clearly contrast to the methodological comparisons of the ICP methods on the toy data (Fig. 2), which respect the normal distributions. If we decompose the proposed causal learning scheme, we witness the suppression of the causal probability on the sanity-check variables over the warm-up stage (steps 1 and 2 of the pseudo code in Fig. 1), whereas the causal variables do not show deterioration of performance. This clear differentiation of causal and non-causal variables can aid the definition of meaningful cut-offs by AutoCI on a given cohort guided by clinical expertise.

Hazard analysis of the individual variables. In parallel to the causal variable determination, the corresponding HR analysis on EC recurrence is also performed. In the scenario in which unknown spurious (non-causal) variables are included in the hazard analysis, the causal cut-off can help reducing the noise introduced by non-causal variables. For instance, Table 2 reports the decreased hazard of tissue area (0.90; 0.88–0.92), Patient ID (0.92; 0.91–0.94) achieved in the warm-up stage for PMI case. Without causal analysis, one may falsely conclude that larger tissue area leads to a slightly lower risk of cancer recurrence. Besides, the HR achieved within the warm-up

Table 2 | The comparison of causal variable determination for the PORTEC dataset among ICP, NICP and the proposed method

	Proposed (warm-up)			Proposed (complete)		
	Causal prob.	HR (95% CI)	P value	Causal prob.	HR (95% CI)	P value
Hazard analysis of P						
Pathological						
Myometrial invasion	55.33%	1.21 (1.17-1.25)	0	52.13%	1.26 (1.21-1.31)	0
Grade	62.72%	1.45 (1.36-1.55)	0	60.71%	1.62 (1.51-1.74)	0
LVSI	60.68%	1.33 (1.26-1.41)	0	59.41%	1.48 (1.39-1.57)	0
Sanity check						
Tissue area	49.31%	0.93 (0.92-0.95)	2.01×10^{-9}	35.96%	NA	NA
Patient ID	50.93%	0.97 (0.96-0.98)	6.05×10^{-16}	20.61%	NA	NA
Hazard analysis of PM						
Pathological						
Myometrial invasion	54.62%	1.34 (1.29-1.39)	0	53.16%	1.43 (1.39-1.48)	0
Grade	60.44%	2.08 (1.95-2.21)	0	60.42%	2.46 (2.33-2.59)	0
LVSI	62.13%	2.01 (1.87-2.16)	0	60.87%	2.44 (2.30-2.60)	0
Molecular						
L1CAM	60.27%	2.00 (1.88-2.12)	0	60.43%	2.33 (2.21-2.45)	0
POLEmut	49.91%	0.94 (0.93-0.96)	4.68×10^{-10}	50.02%	0.94 (0.92-0.95)	1.08×10^{-12}
MMRd	49.20%	0.99 (0.98-1.00)	0.18	49.25%	0.99 (0.98-1.01)	0.31
p53abn	64.67%	2.61 (2.41-2.84)	0	63.92%	3.22 (3.00-3.46)	0
Sanity check						
Tissue area	49.77%	0.89 (0.88-0.91)	0	24.94%	NA	NA
Patient ID	48.98%	0.92 (0.91-0.94)	0	17.48%	NA	NA
Hazard analysis of PMI						
Pathological						
Myometrial invasion	55.22%	1.40 (1.34-1.45)	0	53.84%	1.46 (1.41-1.52)	0
Grade	59.39%	1.97 (1.87-2.08)	0	59.74%	2.22 (2.11-2.34)	0
LVSI	61.88%	2.04 (1.89-2.19)	0	60.56%	2.35 (2.20-2.51)	0
Molecular						
L1CAM	59.91%	1.97 (1.87-2.08)	0	59.92%	2.16 (2.06-2.26)	0
POLEmut	50.08%	0.89 (0.88-0.91)	0	50.46%	0.89 (0.88-0.91)	0
MMRd	49.10%	1.02 (1.01-1.04)	0.0004	49.40%	1.05 (1.04-1.07)	6.90×10^{-12}
p53abn	63.82%	2.65 (2.44-2.87)	0	62.91%	3.01 (2.80-3.22)	0
Immune						
CD8+ cell density	56.33%	0.64 (0.61-0.66)	0	56.14%	0.59 (0.57-0.61)	0
Sanity check						
Tissue area	49.58%	0.90 (0.88-0.92)	0	21.12%	NA	NA
Patient ID	49.18%	0.92 (0.91-0.94)	0	22.89%	NA	NA

The hazard analysis including hazard ratios (HRs), 95% confidence intervals (CIs) and P values for P, PM and PMI, where the P value is computed from the χ^2 test. The proposed (warm-up) refers to steps 1 and 2 of the pseudo code in Fig. 1.

and complete learning stage remains stable and consistent to the standard clinical interpretation, that is, the values assigned to the variable indeed correctly correspond to either poor or favourable outcomes. This learning scheme can therefore help delivering reliable outputs that are understandable for clinical experts.

Ablation study with hidden confounders. To elaborate the robustness of AutoCI, we conducted ablation studies with the influence of confounding. This is achieved by step-wise inclusion of P and PM. As shown in Tables 1 and 2, the proposed AutoCI presents consistent advantages over the existing ICP methods in terms of learning

meaningful causal probabilities for both non-causal and causal variables. For instance, the tissue area and Patient ID are determined to be 35.96% and 20.61% for P, and 24.94% and 17.48% for PM, respectively, whereas the causal probabilities of all of the proxy variables remain close to or above 50%. In the hazard analysis, the results of the confounding studies P and PM are also consistent with the results reported for the main study (PMI). For instance, L1CAM and p53abn are assigned with increased hazards for PM and PMI, indicating a poor prognostic outcome. These results are in agreement with clinical understanding^{27,29,33}. The numerical improvements from P to PMI in the accuracy of probabilistic predictions




Fig. 3 | The evaluation metrics of hazard analysis conducted on the PORTEC dataset. Box plots of the concordance index (left), Brier score (middle), and the binomial log-likelihood (right) that are derived from $n = 640$ patients included in the PORTEC dataset, where the box bounds the interquartile range (IQR) divided by the median, and whiskers extend to $\pm 1.5 \times \text{IQR}$ beyond the box.

(Fig. 3) provide complementary evidence confirming the robustness of AutoCI. When compared with the warm-up stage of AutoCI, we further observe a reduction in variance in the evaluation of the complete causal-aware AutoCI. Finally, the running time of the P, PM and PMI studies grows only mildly for the proposed method, in contrast to the dramatic increase in time complexity for ICP and NICP, where the bottleneck of the ICPs lies in the exponential increase $o(2^{|S|})$ in search space with the growing number of variables S (equation (3)).

Discussion

In this study, we proposed a novel automated causal inference algorithm (AutoCI). Taking two large RCTs as the experimental environments, we reinterpret the clinical variables of interest from a causal perspective. The proposed AutoCI demonstrates consistent advantages compared with existing ICP methods in determining causal variables with the presence of hidden confounders. Complementary to the standard hazard analysis, AutoCI provides an automatic tool for medical data analysis to investigate causal association of patient variables from a new perspective, offering informative and critical evidence to support clinical interpretation. Specifically, the accurate determination and exclusion of the spurious (non-causal) variables is a key step to enable more precise patient stratification in the future.

Design choices of AutoCI. Dissimilar to generic algorithms, clinical algorithms must deal with unique challenges in terms of ensuring the safety⁴³ and robustness. Error-prone algorithms can potentially lead to critical errors in medical care. Driven by the need to develop safe-critical applications, AutoCI is carried out with a type-safe program synthesis method⁴². By further incorporating a newly proposed causal-aware module into this framework, we are able to synthesize a subset of differentiable type-safe candidates well suited for causal-aware learning. Compared to the laborious and error-prone manual function design, this implementation improves the efficiency and safety of AutoCI. Moreover, to achieve the robustness on the real clinical tasks, we introduce a novel causal differentiable learning scheme that utilizes the Fréchet inception distance (FID)⁴⁴. As a whole, the proposed AutoCI is the seamless integration of both components.

Comparison with existing ICPs. Application of the prior ICP methods has confirmed the feasibility of causal variable learning on toy experiments (Table 3 and Fig. 2). This is substantiated by the outstanding results in the absence of confounders; however, the error-tolerant implementations of prior ICPs on the synthesized

Table 3 | The comparison of causal variable determination for the toy datasets between ICPs and the proposed method

Finite sample setting ^a			
	JS (FWER)		
	Two confounders	One confounder	Zero confounders
ICP	0.332 (0.98)	0.382 (0.85)	1.00 (0.00)
NICP	0.333 (0.98)	0.384 (0.85)	1.00 (0.00)
AICP	0.439 (0.05)	0.483 (0.11)	0.998 (0.0004)
Proposed	0.911 (0.13)	0.923 (0.14)	0.994 (0.006)
ABCD setting ^b			
	JS (FWER)		
	Two confounders	One confounder	Zero confounders
ICP	0.517 (0.61)	0.559 (0.51)	0.976 (0.00)
NICP	0.512 (0.69)	0.558 (0.57)	0.992 (0.002)
AICP	0.417 (0.12)	0.437 (0.18)	0.991 (0.01)
Proposed	0.922 (0.08)	0.928 (0.12)	0.985 (0.02)

^aThe results of the compared methods for the finite sample setting. ^bThe results of the compared methods for the ABCD setting.

experiments are not well-tailored for real clinical applications, especially in the presence of hidden confounders. Compared with ICP, AICP and NICP, AutoCI presents robust results on both toy and PORTEC experiments. With the inclusion of confounders, AutoCI demonstrated a robust differentiation between causal and non-causal variables for PORTEC, and achieves superior quantitative scores on both the finite sample and ABCD settings.

Clinical interpretations. Importantly, the hazard analysis and ranking of clinicopathological and molecular variables using AutoCI (Table 1) is generally consistent with the common biological and clinical interpretation. Taking pathological variables as an example, studies^{26–28} indeed show that grade, deep myometrial invasion and LVSI are important independent predictors of early EC recurrence. The causal probabilities provided by AutoCI thereby give additional information on the relevance of each variable for the determination of outcome, and the likelihood of each variable is consistent with domain expertise. Lymphovascular space invasion is considered to be a critical predictor independent of molecular subgroup and is ranked with the highest causal probability, while

grade and myometrial invasion are indeed weaker but independent prognostic indicators.

Furthermore, AutoCI correctly identifies the prognostic associations of the molecular variables of EC, assigns the appropriate hazards for outcome and ranks the molecular subgroups in the order of causal probability that would be expected by an expert's domain knowledge. Specifically, the molecular factors with the highest adverse risk, p53 abnormality (3.01 (PMI), 3.22 (PM)) and L1CAM over-expression (2.16 (PMI), 2.33 (PM))³³ are recognized as such, whereas the POLEmut is consistently associated with a reduced risk of disease relapse as confirmed in previous studies³⁰. Adding an immune variable further refines the model, as expected by domain expertise³, and highlights a causal relationship between cytotoxic T-cell responses and EC recurrence in early stage EC. In summary, AutoCI correctly quantifies and ranks causal pathological, molecular and immune variables for patient outcomes in the clinical trial setting.

Going beyond academic toy models, the proposed AutoCI extends the researchers current statistical toolbox with a new causal-driven method that can assign the causal likelihood to prognostic and predictive variables. As such, this method will enable identification of clinically relevant variables among the ever-increasing number of biomarkers in cancer research that show statistical correlation with clinical outcome. Hence, although the direct real-world application of this method is primarily scientific, subsequent clinical validation and development may enable better selection of (bio)markers to stratify patients for cancer treatments and prediction of prognosis.

Limitation

Despite the clear cut-off between non-causal and proxy variables provided by AutoCI, some of the proxy variables present borderline hazard ratios, for instance, MMRd. Due to small effect size, clinical studies^{45,46} usually associate MMRd with intermediate patient prognosis, not much different from the prognosis of NSMP EC; however, from the biological perspective, MMRd is highly relevant for a well-defined cascade of molecular changes in cancer cells with favourable prognostic impact as proven by a large number of well-designed experimental and translational studies^{31,47}. The loss of DNA mismatch repair capability in cancer cells leads to a strong increase in tumour mutational burden caused by mismatch, frameshift and insertion/deletion mutations. Due to the structure of eucaryotic DNA, frameshift mutations frequently lead to the translation of truncated peptides that are highly immunogenic, and contribute to the induction of an effective anti-tumoral immune response⁴⁷. Consistent with biological understanding, AutoCI identifies MMRd as causally related to outcome in the present study, although the lack of a strong association with EC recurrence requires further investigation.

Conclusion

In this study we investigate the causal variable determination among multiple RCTs and present its advantages over the compared methods on both toy and PORTEC experiments. For clinical application, further validation of this methodology in independent clinical trial datasets will be needed to ensure generalisation.

Methods

As per the AutoCI abbreviation, automated and causal are the two building blocks of the proposed method. Concretely, the automation component is implemented with a type-safe program synthesis language HOUDINI⁴². We also introduce a novel differentiable causal learning scheme that is built up ICP.

Type-safe program synthesis. HOUDINI⁴² is a typed language with a rich set of pythonic higher-order functions such as MAP, FOLD, COMP (Pythonic: `map()`, `reduce()`, `lambda x: f(g(x))`) and so on (Fig. 1, top left). Relying on the built-in method for program search, it allows us to efficiently search promising type-safe differentiable program candidates. Compared with other program synthesis languages^{48–51}, HOUDINI rules out the error-prone functions that

undermine the software safety and presents itself as an ideal candidate for our task (see Supplementary Table 5 for further comparison).

Despite of rich built-in functions provided by the HOUDINI, it lacks an explicit flow control mechanism. Driven by the need of integrating the causal-aware learning, we introduce the predicate module (PRED) containing the function (cau) (see also Fig. 1, top left)

$$\text{cau}(\mathbf{x}; \boldsymbol{\theta}) = \text{mask} \odot \text{sigmoid}(\boldsymbol{\theta}) \odot \mathbf{x}, \quad (5)$$

where $\boldsymbol{\theta}$ represents the learnable weights (normalized by sigmoid), \odot is the element-wise multiplication, mask is the vector containing 0 or 1 manipulated in step 5 of Fig. 1 (top), $\text{mask} \odot \text{sigmoid}(\boldsymbol{\theta})$ presents the causal probability for each variable. Together with the newly introduced higher-order function FILTER, we are able to synthesize type-safe causal-aware programs.

Causal differentiable learning. In Definition 1, the ICP does not make assumptions about the function f^* (equation (1)). In real-world applications, it is reasonable to specify the search space of f^* . If we assume that f^* is differentiable, then we have a trivial extension:

$$f: \mathbb{R}^n \mapsto \mathbb{R} \\ \underbrace{X_{i_0}, \dots, X_{i_{|\hat{S}^*|}}}_{X_{S^*}}, \underbrace{X_{i_{|\hat{S}^*|+1}}, \dots, X_{i_n}}_{X_{S^{*c}}} \rightarrow f^*(\mathbf{X}_{S^*}), \quad \forall u \in U, \quad (6)$$

where f remains differentiable with regards to all of the variables \mathbf{X} . More importantly, the gradient norms with regards to the non (plausible) causal variables $X_{S^{*c}}$ should vanish, that is, $\|\nabla_{S^{*c}} f\| = 0$. Motivated by the extension, we first assume f^* to be differentiable in Definition 1, then we have the claim:

Claim 1. Following the specification of U , $\mathbf{X} = (X_1, X_2, \dots, X_n)$ and Y in Definition 1, if $\mathbf{X}_{\hat{S}} = (X_{\hat{S}_1}, \dots, X_{\hat{S}_k})$ with indices $\hat{S} \subseteq \{1, \dots, n\}$ are the identifiable causal variables, then there exists a differentiable function $f(\mathbf{X}): \mathbb{R}^n \mapsto \mathbb{R}$ satisfying equations (1) and (2) such that f has the maximum amount $|\hat{S}^*|$ of variables with $\|\nabla_{\hat{S}^*} f\| = 0$.

From this perspective, we can reduce the ICPs to learning an invariant differentiable function f , where f has the (maximum amount of) vanishing gradient norms on the non-causal variables. Such reduction enables us to smoothly integrate the ICP into the modern differentiable learning framework.

Algorithm design. To impose the vanishing gradient norms, we seek for the mask vector in equation (5) as the solution. Initially, we assign $\text{mask} = 1$ for all the variables. Assume we mask a causal variable X_i by flipping $\text{mask}_i = 0$, then it should greatly disturb the learning errors across multiple environments. If this is the case, we restore $\text{mask}_i = 1$ and take X_i as the causal variable. Otherwise we reject the variable X_i and mask_i remains as 0, which imposes the zero gradient with respect to X_i . To quantify the disturbance when variables of interest are missing, existing ICPs use several statistical tests^{52–54}. These tests suffer from capturing the nuance of distributions related to higher-dimensional clinical data. Motivated by the recent success in complex vision data⁵⁵, we utilize the FID⁴⁴, which is derived from the Wasserstein distance⁵⁶. More specifically, the square root of FID between Gaussian distributions is exactly W_2 Wasserstein distance⁵⁶, that is, satisfying three axioms (identity, symmetry and triangular inequality), whereas the statistical tests used in refs. ^{23–25} are generally not mathematical metrics. As a result, the maximum FID (mFID) of U is proposed to measure the distribution difference,

$$\text{mFID} = \max_{u \in U} \text{FID}(\mu_u, \mu_{u^c}), \quad (7)$$

where μ_u, μ_{u^c} are the distributions with regards to the data sampled from the environment(s) $\{u\}$ and $\{u^c\}$. Supplementary Table 6 presents side by side comparisons between mFID, F -test + t -test^{23,25} and Levene-test + Wilcoxon-test²⁴, all of which are applied for training the same type-safe function COMP(NN, CAT(FILTER(PRED))) under the proposed causal differentiable learning scheme. As displayed in Supplementary Table 6, we conclude that the proposed mFID outperforms the compared statistical tests with a clear margin. For the pseudo code of proposed algorithm please check the top plot of Fig. 1 (in the 'causal differential learning' box).

Proof of concept. For the sake of concept validation, we first conduct experiments on toy datasets. We compare the proposed AutoCI to the SOTA methods ICP, NICP and AICP. Specifically, we follow the two experimental protocols presented in AICP²⁵: finite sample setting and ABCD setting⁵⁷. The former presents the ideal scenario where the same amount of data (1,000) are sampled from both observational and experimental (interventional) environments, whereas the latter simulates a more realistic case where limited experimental data (10) are collected in conjunction with a large amount of observational data (1,000). The data of both settings are generated from randomly chosen linear structural causal models. In our experiments, 400 structural causal models are tested to guarantee the reliability of our results. For the compared ICP methods, we applied the optimal strategies discussed in the paper and parameters are fine-tuned to the experiments. Specifically, careful parallelization and code optimization is also performed for

ICP methods. We use 16 cores of CPU Intel(R) Core(TM) i7-7820X CPU @ 3.60 GHz to train the ICP methods in parallel and the GPU NVIDIA TITAN V (12 GB) to train the AutoCI. For the proposed AutoCI, we use the standard Adam optimization⁵⁸ at a learning rate of 0.02 throughout the experiments. For the warm-up stage (steps 1 and 2 of Fig. 1) of causal differentiable learning we adopt eight epochs. The batch size is set to be 64 for all the experiments. We calibrate the $\lambda = 5, 1$ for toy and PORTEC on a small subset of unused data. For the toy experiment, we apply the MSE loss to supervise the learning process and report the result obtained by training the AutoCI one time, where the non-causal variable is determined to be the one with 0 causal probability (equation (5)). For the PORTEC experiment, we utilize the partial likelihood to learn the hazard coefficient⁵⁹. To fully utilize the PORTEC patient data and incorporate into the differentiable cox model⁵⁹, the molecular subtype variables PLEmut, MMRd and p53abn are assigned with 1 if present else (including NSMP) 0. To guarantee the representativeness of the PORTEC results, we independently train the AutoCI 64 times and average the causal probability for each variable. Complementary to JS score, we also report $\text{FWER} = P(S_{\text{PRED}} \notin S_{\text{prox}})$ (type-I error).

As shown in Table 3, our AutoCI achieved competitive JS and FWER scores compared to the ICP methods. Clearly, the proposed method is more resistant to the influence of hidden confounders and all the results reach >90% JS accuracy. This is achieved by the optimal type-safe function $\text{COMP}(\text{NN}, \text{CAT}(\text{FILTER}(\text{PRED})))$ (Fig. 2, left and middle; Supplementary Tables 7 and 8). Such advantages also confirm the effectiveness of the proposed causal learning scheme with the utilization of mFID metric. Similar to the PORTEC experiments, due to the exhaustive subset research required in equation (3), the time complexity of ICP and NIPC raises dramatically from ABCD to finite sample settings (Fig. 2, right).

Ethics statement. The PORTEC study protocols were approved by the Dutch Cancer Society and by the medical ethics committees at participating centers. Both studies were conducted in accordance with the principles of the Declaration of Helsinki. All patients provided informed consent for study participation. The PORTEC 1 trial was registered at the Daniel Den Hoed Cancer Center (DDHCC) Trial Office. The PORTEC 2 trial was registered at ClinicalTrials.gov under the identifier NCT00376844.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The PORTEC dataset analysed in this study is not publicly available due to restrictions by privacy laws. The dataset and tumour material are currently available to the members of the international TransPORTEC consortium, which is open to requests for sharing of the data and materials after receipt and evaluation of a scientific proposal. Requests should be addressed to the corresponding authors. Please contact N.H. at n.horeweg@lumc.nl for more details. Depending on the specific research proposal, the TransPORTEC consortium will determine when, for how long, for which specific purposes, and under which conditions the requested data can be made available, subject to ethical consent.

Code availability

The code used to generate the data of the toy experiments is available at <https://github.com/juangamella/aicp>. Our code is implemented with PyTorch and publicly accessible at <https://github.com/CTPLab/AutoCI>, which is released under the MIT licence.

Received: 23 July 2021; Accepted: 23 February 2022;

Published online: 25 April 2022

References

- Pearl, J. Causal inference in the health sciences: a conceptual introduction. *Health Serv. Outcomes Res. Methodol.* **2**, 189–220 (2001).
- Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* **397**, 99–111 (2021).
- Horeweg, N. et al. Prognostic integrated image-based immune and molecular profiling in early-stage endometrial cancer. *Cancer Immunol. Res.* **8**, 1508–1519 (2020).
- Hariton, E. & Locascio, J. J. Randomised controlled trials—the gold standard for effectiveness research. *BJOG* **125**, 1716 (2018).
- Peters, J., Janzing, D. & Schölkopf, B. *Elements of Causal Inference* (MIT Press, 2017).
- Creutzberg, C. L. et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. *Lancet* **355**, 1404–1411 (2000).
- Creutzberg, C. L. et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. *Int. J. Radiat. Oncol. Biol. Phys.* **81**, e631–e638 (2011).
- Nout, R. A. et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. *Lancet* **375**, 816–823 (2010).
- Wortman, B. et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. *Br. J. Cancer* **119**, 1067–1074 (2018).
- Sung, H. et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **71**, 209–249 (2021).
- van den Heerik, A. S. V., Horeweg, N., de Boer, S. M., Bosse, T. & Creutzberg, C. L. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. *Int. J. Gynecol. Cancer* **31**, 594–604 (2021).
- Concin, N. et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. *Int. J. Gynecol. Cancer* **31**, 12–39 (2021).
- Hernán, M. A. & Robins, J. M. *Causal Inference: What If* (CRC, 2020).
- Zenil, H., Kiani, N. A., Zea, A. A. & Tegnér, J. Causal deconvolution by algorithmic generative models. *Nat. Mach. Intell.* **1**, 58–66 (2019).
- Prosperi, M. et al. Causal inference and counterfactual prediction in machine learning for actionable healthcare. *Nat. Mach. Intell.* **2**, 369–375 (2020).
- Luo, Y., Peng, J. & Ma, J. When causal inference meets deep learning. *Nat. Mach. Intell.* **2**, 426–427 (2020).
- Pearl, J. et al. Causal inference in statistics: an overview. *Stat. Surv.* **3**, 96–146 (2009).
- Hernán, M. A., Sauer, B. C., Hernández-Díaz, S., Platt, R. & Shrier, I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. *J. Clin. Epidemiol.* **79**, 70–75 (2016).
- Dickerman, B. A., García-Albéniz, X., Logan, R. W., Denaxas, S. & Hernán, M. A. Avoidable flaws in observational analyses: an application to statins and cancer. *Nat. Med.* **25**, 1601–1606 (2019).
- Caniglia, E. C. et al. Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes. *AIDS* **32**, 113 (2018).
- Dahabreh, I. J., Robertson, S. E., Steingrimsson, J. A., Stuart, E. A. & Hernán, M. A. Extending inferences from a randomized trial to a new target population. *Stat. Med.* **39**, 1999–2014 (2020).
- Zhu, S., Ng, I. & Chen, Z. *Causal Discovery with Reinforcement Learning* (ICLR, 2019).
- Peters, J., Bühlmann, P. & Meinshausen, N. Causal inference by using invariant prediction: identification and confidence intervals. *J. R. Stat. Soc. B* **78**, 947–1012 (2016).
- Heinze-Deml, C., Peters, J. & Meinshausen, N. Invariant causal prediction for nonlinear models. *J. Causal Inference* <https://doi.org/10.1515/jci-2017-0016> (2018).
- Gamella, J. L. & Heinze-Deml, C. Active invariant causal prediction: experiment selection through stability. *Adv. Neural Inf. Process. Syst.* **33**, 15464–15475 (2020).
- Scholten, A. N. et al. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. *Int. J. Radiat. Oncol. Biol. Phys.* **63**, 834–838 (2005).
- Stelloo, E. et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer—combined analysis of the PORTEC cohorts. *Clin. Cancer Res.* **22**, 4215–4224 (2016).
- Bosse, T. et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer—a pooled analysis of PORTEC 1 and 2 trials. *Eur. J. Cancer* **51**, 1742–1750 (2015).
- Kandath, C. et al. Mutational landscape and significance across 12 major cancer types. *Nature* **502**, 333–339 (2013).
- Church, D. N. et al. Prognostic significance of pole proofreading mutations in endometrial cancer. *J. Natl Cancer Inst.* **107**, 402 (2015).
- Stelloo, E. et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. *Modern Pathol.* **28**, 836–844 (2015).
- Vermij, L., Smit, V., Nout, R. & Bosse, T. Incorporation of molecular characteristics into endometrial cancer management. *Histopathology* **76**, 52–63 (2020).
- Bosse, T. et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. *Eur. J. Cancer* **50**, 2602–2610 (2014).
- Van Gool, I. C. et al. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. *Modern Pathol.* **29**, 174–181 (2016).
- Koelzer, V. H., Sirinukunwattana, K., Rittscher, J. & Mertz, K. D. Precision immunopathology using histology analysis and artificial intelligence. *Virchows Arch.* **474**, 511–522 (2019).

36. Zlobec, I., Koelzer, V. H., Dawson, H., Perren, A. & Lugli, A. Next-generation tissue microarray (NGTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types. *J. Transl. Med.* **11**, 1–7 (2013).
37. Creutzberg, C. L. et al. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. *Int. J. Radiat. Oncol. Biol. Phys.* **91**, 530–539 (2015).
38. Karnezis, A. N. et al. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. *J. Pathol. Clin. Res.* **3**, 279–293 (2017).
39. Allouk, A. et al. Molecular subtype not immune response drives outcomes in endometrial carcinoma. *Clin. Cancer Res.* **25**, 2537–2548 (2019).
40. Lipsitch, M., Tchetgen, E. T. & Cohen, T. Negative controls: a tool for detecting confounding and bias in observational studies. *Epidemiology* **21**, 383 (2010).
41. Yang, J. & Hawblitzel, C. Safe to the last instruction: automated verification of a type-safe operating system. In *Proc. 31st ACM SIGPLAN Conference on Programming Language Design and Implementation* 99–110 (ACM, 2010).
42. Valkov, L., Chaudhari, D., Srivastava, A., Sutton, C. & Chaudhuri, S. HOUDINI: lifelong learning as program synthesis. In *32nd Conference on Neural Information Processing Systems* 8687–8698 (NeurIPS, 2018).
43. Allen, B. The role of the FDA in ensuring the safety and efficacy of artificial intelligence software and devices. *J. Am. College Radiol.* **16**, 208–210 (2019).
44. Heusel, M., Ramsauer, H., Unterthiner, T., Nessler, B. & Hochreiter, S. Gans trained by a two time-scale update rule converge to a local Nash equilibrium. In *31st Conference on Neural Information Processing Systems* 6626–6637 (NeurIPS, 2017).
45. Smyth, E. C. et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial. *JAMA Oncol.* **3**, 1197–1203 (2017).
46. León-Castillo, A. et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. *J. Clin. Oncol.* **38**, 3388–3397 (2020).
47. Kloor, M. & von Knebel Doeberitz, M. The immune biology of microsatellite-unstable cancer. *Trends Cancer* **2**, 121–133 (2018).
48. Gaunt, A. L., Brockschmidt, M., Kushman, N. & Tarlow, D. *Differentiable Programs with Neural Libraries* 1213–1222 (ICLR, 2017).
49. Mao, J., Gan, C., Kohli, P., Tenenbaum, J. B. & Wu, J. *The Neuro-Symbolic Concept Learner: Interpreting Scenes, Words, and Sentences From Natural Supervision* (ICLR, 2018).
50. Vedantam, R. et al. *Probabilistic Neural Symbolic Models for Interpretable Visual Question Answering* 6428–6437 (ICLR, 2019).
51. Ellis, K. et al. Dreamcoder: growing generalizable, interpretable knowledge with wake-sleep Bayesian program learning. Preprint at <https://arxiv.org/abs/2006.08381> (2020).
52. Pfanzagl, J. & Sheynin, O. Studies in the history of probability and statistics XLIV a forerunner of the *t*-distribution. *Biometrika* **83**, 891–898 (1996).
53. Levene, H. in *Contributions to Probability and Statistics: Essays in Honor of Harold Hotelling* 279–292 (Stanford Univ. Press, 1961).
54. Wilcoxon, F. *Individual Comparisons by Ranking Methods: Breakthroughs in Statistics* 196–202 (Springer, 1992).
55. Lucic, M., Kurach, K., Michalski, M., Gelly, S. & Bousquet, O. Are GANs created equal? A large-scale study. *Adv. Neural Inf. Process. Syst.* **31**, 1–10 (2018).
56. Villani, C. *Optimal Transport: Old and New* Vol. 338 (Springer, 2008).
57. Agrawal, R., Squires, C., Yang, K., Shanmugam, K. & Uhler, C. ABCD-strategy: budgeted experimental design for targeted causal structure discovery. In *22nd International Conference on Artificial Intelligence and Statistics* 3400–3409 (National Science Foundation, 2019).
58. Kingma, D. P. & Ba, J. *Adam: A Method for Stochastic Optimization* (ICLR, 2015).
59. Kvamme, H., Borgan, Ø. & Scheel, I. Time-to-event prediction with neural networks and Cox regression. *J. Mach. Learn. Res.* **20**, 1–30 (2019).

Acknowledgements

We convey our gratitude to all clinicians and technicians that participated in the PORTEC 1 and 2 trials (registration no. ISRCTN16228756), and all scientists, pathologists and patients involved in the data processing and analysis. The PORTEC 1 and 2 trials were supported by the grants from the Dutch Cancer Society (grant nos. CKTO 90–01 and CKTO 2001–04, respectively). Molecular profiling was supported by the grants from the Dutch Cancer Society (grant nos. KWF UL2012-5447 and KWF/YIG 10418, respectively). V.H.K. reports a grant from the Promedica Foundation (grant no. F-87701-41-01) during the conduct of the study. N.H. reports grants from the Dutch Cancer Society (grant nos. KWF-2021-13400, KWF-2021-13404) during the conduct of the study.

Author contributions

J.Q.W. and V.H.K. conceived the research idea. J.Q.W. implemented the algorithm and ran the experiments. J.Q.W., V.H.K. and N.H. analysed the data and results. J.Q.W. and V.H.K. wrote the manuscript. N.H. and V.H.K. reviewed the manuscript and supervised this study. R.A.N., I.M.J.-S., J.J.J., L.C.H.W.L., E.M.v.d.S.-B., T.B., C.L.C., M.d.B., H.W.N., T.B. and V.T.H.B.M.S. provided the PORTEC 1 and 2 trials data. C.L.C. and V.T.H.B.M.S. conceptualized and designed the PORTEC 1 and 2 study. R.A.N., T.B., C.L.C. and V.T.H.B.M.S. supervised the PORTEC 1 and 2 study.

Competing interests

The authors declare no competing interests.

Additional information

Extended data is available for this paper at <https://doi.org/10.1038/s42256-022-00470-y>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s42256-022-00470-y>.

Correspondence and requests for materials should be addressed to Ji Q. Wu or Viktor H. Koelzer.


Peer review information *Nature Machine Intelligence* thanks Miquel Porta and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>. © The Author(s) 2022



Extended Data Fig. 1 | The consort diagram presenting the process of patient selection. Abbreviations: QC - quality control, IHC - immunohistochemistry, EEC- endometrioid endometrial carcinoma, NEEC- non-endometrioid endometrial carcinoma.

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection Python 3.9, <https://github.com/juagamella/aicp.git>

Data analysis Python 3.9, PyTorch 1.10, <https://github.com/CTPLab/AutoCl.git>, <https://github.com/juagamella/aicp.git>

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The PORTEC dataset analysed in this study are not publicly available due to restrictions by privacy laws. The dataset and tumour material are currently available to the members of the international TransPORTEC consortium, and the consortium is open for requests for sharing of the data and material after receipt and evaluation of a scientific proposal. Requests should be addressed to the corresponding author. Please contact Dr. Horeweg via n.horeweg@lumc.nl for more details. Depending on the specific research proposal, the TransPORTEC consortium will determine when, for how long, for which specific purposes, and under which conditions the requested data can be made available, subject to ethical consent. The code used to generate the data of the toy experiments is available via the link <https://github.com/juagamella/aicp>.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	<p>The PORTEC 1 (Creutzberg et al., 2000) and 2 (Nout et al., 2010) trials recruited 714 (since 1990 - 1997) and 427 (since 2000 - 2006) patients with early stage endometrial carcinoma respectively.</p> <p>Note: Our work is a secondary causal analysis on existing PORTEC 1 and 2 clinical trials. For more details about the clinical trials, see also Creutzberg, Carien L., et al. "Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial." <i>The Lancet</i> 355.9213 (2000): 1404-1411.</p> <p>Nout, R. A., et al. "Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial." <i>The Lancet</i> 375.9717 (2010): 816-823.</p>
Data exclusions	In our study, 305 cases from PORTEC 1 (42.7%) and 335 cases from PORTEC 2 (78.5%) with complete clinicopathological datasets were aligned and used in the experiments.
Replication	In our study, to verify the experimental finds, we re-run the algorithmic codes multiple times with undetermined random seeds. Almost all the experiments presented clear causal variable differentiations. The minor failure cases are mainly due to the intrinsic randomness of the proposed algorithm.
Randomization	<p>PORTEC 1: Patients with stage-1 endometrial carcinoma (grade 1 with deep [$\geq 50\%$] myometrial invasion, grade 2 with any invasion, or grade 3 with superficial [$< 50\%$] invasion) were enrolled. Patients from 19 radiation oncology centres were randomised to pelvic radiotherapy (46 Gy) or no further treatment. Central blocked randomisation by telephone was done at the DDHCC trial office with variable block sizes and stratified by radiation oncology centre and depth of myometrial invasion ($< 50\%$ vs $\geq 50\%$).</p> <p>PORTEC 2: Patients with endometrial adenocarcinoma were eligible for the trial on the basis of the following features of high-intermediate risk: (1) age greater than 60 years and stage 1C grade 1 or 2 disease, or stage 1B grade 3 disease; and (2) stage 2A disease, any age (apart from grade 3 with greater than 50% myometrial invasion). Participants were assigned to either EBRT or VBT via internet with an application trial online process (TOP). Patient details and answers about eligibility questions were entered by the data managers of the participating centres, after which the treatment was allocated by TOP with a biased coin minimisation procedure, with stratification factors FIGO stage, radiotherapy centre, brachytherapy (low-dose vs high-dose rate), and patient age (< 60 years vs ≥ 60 years).</p> <p>For more details about the PORTEC clinical trials see Creutzberg et al., 2000 and Nout et al., 2010.</p>
Blinding	The investigators were blinded to group allocation during data collection and/or analysis.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants
<input type="checkbox"/>	<input checked="" type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics

PORTEC 1: Age <60: 201 (28%), 60-70: 270 (38%), >70: 243 (34%).
Grade 1: 142 (41%), 2: 498 (70%), 3: 74 (10%).

PORTEC 2: Age <60: 16 (4%), 60-70: 208 (49%), >70: 203 (47%).
Grade 1: 202 (47%), 2: 191 (45%), 3: 34 (8%).

See more population characteristics in Creutzberg et al., 2000 and Nout et al., 2010.

Recruitment

Note: Our work is a secondary causal analysis on existing PORTEC 1 and 2 clinical trials. For more details about the clinical trials, see also:

Creutzberg, Carien L., et al. "Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial." *The Lancet* 355.9213 (2000): 1404-1411.

Nout, R. A., et al. "Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediaterisk (PORTEC-2): an open-label, non-inferiority, randomised trial." *The Lancet* 375.9717 (2010): 816-823.

PORTEC 1: All but one of the 20 radiation oncology centres in the Netherlands took part. The patients were evaluated and treated by their local gynaecologist, most often a general gynaecologist with special interest in gynaecological oncology. Initial evaluation included a pelvic examination, and endometrial curettage with separate endocervical and endometrial sampling. Preoperative evaluation included a medical history and physical and pelvic examination, chest radiography, complete blood count, and blood-chemistry tests. An abdominal computed-tomography scan was optional. At the time of surgery, a median laparotomy was done and, after obtaining a peritoneal cytology specimen, abdominal exploration with careful palpation and biopsy of any suspicious lymph nodes or lesions was done. A total abdominal hysterectomy and bilateral salpingo-oophorectomy was done, without routine lymphadenectomy. The diagnoses of endometrial carcinoma, of the histological grade, histological subtype, and depth of myometrial invasion were made by the regional pathologist. Vascular space invasion and perineural invasion were noted if present. FIGO 1988 staging³⁰ was assigned on the basis of surgical and pathological findings.

Women of any age with a histologically proven endometrial adenocarcinoma (also including adenocarcinoma with squamous features, adenocarcinoma not otherwise specified, adenosquamous carcinoma, papillary serous carcinoma, and clear-cell carcinoma), postoperative FIGO stage I, grade 1 with deep ($\geq 50\%$) myometrial invasion, grade 2 with any invasion, or grade 3 with superficial ($< 50\%$) invasion were eligible for the study. While peritoneal cytology was recommended, patients were not excluded if this had not been done. All patients had a WHO-performance score of 0–2. Patients were excluded if they had a history of invasive cancer (except for basal cell carcinoma of the skin), and if they had previously received chemotherapy, hormonal therapy, or radiotherapy. The interval between surgery and radiotherapy had to be less than 8 weeks. Informed consent was obtained from all patients.

PORTEC 2: The PORTEC-2 trial was a multicentre randomised trial, in which 19 of the 21 Dutch radiation oncology centres participated. The study was undertaken between May 27, 2002, and Sept 25, 2006. Patients were assessed and operated on by their regional gynaecologist. Initial assessment included pelvic examination and endometrial tissue biopsy. Preoperative assessment included chest radiography and haematology and chemistry tests. During surgery a peritoneal cytology specimen was obtained and abdominal exploration undertaken. Surgery consisted of total abdominal hysterectomy and bilateral salpingo-oophorectomy; clinically suspicious pelvic or periaortic lymph nodes were removed, but no routine lymphadenectomy was done. Diagnosis, typing, and grading of endometrial carcinoma was done by the regional pathologist. FIGO 1988 staging was assigned on the basis of surgical and pathological findings.

Patients with endometrial adenocarcinoma were eligible for the trial on the basis of the following features of high-intermediate risk: (1) age greater than 60 years and stage 1C grade 1 or 2 disease, or stage 1B grade 3 disease; and (2) stage 2A disease, any age (apart from grade 3 with greater than 50% myometrial invasion). All patients had a WHO performance score of 0–2. Exclusion criteria were: serous or clear cell carcinoma; staging lymphadenectomy; interval between surgery and radiotherapy more than 8 weeks; history of previous malignant disease; previous radiotherapy, hormonal therapy, or chemotherapy; and previous diagnosis of Crohn's disease or ulcerative colitis.

Ethics oversight

The PORTEC study protocols were approved by the Dutch Cancer Society and by the medical ethics committees at participating centers. Both studies were conducted in accordance with the principles of the Declaration of Helsinki. All patients provided informed consent for study participation.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration

PORTEC 1: Daniel Den Hoed Cancer Center Trial Office (DDHCC)
PORTEC 2: NCT00376844

Study protocol	Note: Our work is a secondary causal analysis on existing PORTEC 1 and 2 clinical trials. See more protocol details in Creutzberg et al., 2000 and Nout et al., 2010.
Data collection	<p>PORTEC 1: All but one of the 20 radiation oncology centres in the Netherlands took part in patient data collection during 1990 - 1007.</p> <p>PORTEC 2: 19 of the 21 Dutch radiation oncology centres in the Netherlands participated in the data collection and assessment since 2000-2006.</p> <p>See more data collection details in Creutzberg et al., 2000 and Nout et al., 2010.</p>
Outcomes	<p>PORTEC 1: 5-year actuarial locoregional recurrence rates were 4% in the radiotherapy group and 14% in the control group (p0.001). Actuarial 5-year overall survival rates were similar in the two groups: 81% (radiotherapy) and 85% (controls), p0.31. Endometrial-cancer-related death rates were 9% in the radiotherapy group and 6% in the control group (p=0.37). Treatment-related complications occurred in 25% of radiotherapy patients, and in 6% of the controls (p0.0001). Two-thirds of the complications were grade 1. Grade 3–4 complications were seen in eight patients, of which seven were in the radiotherapy group (2%). 2-year survival after vaginal recurrence was 79%, in contrast to 21% after pelvic recurrence or distant metastases. Survival after relapse was significantly (p0.02) better for patients in the control group. Multivariate analysis showed that for locoregional recurrence, radiotherapy and age below 60 years were significant favourable prognostic factors.</p> <p>PORTEC 2: At median follow-up of 45 months (range 18–78), three vaginal recurrences had been diagnosed after VBT and four after EBRT. Estimated 5-year rates of vaginal recurrence were 1.8% (95% CI 0.6-5.9) for VBT and 1.6% (0.5–4.9) for EBRT (hazard ratio [HR] 0.78, 95% CI 0.17–3.49; p=0.74). 5-year rates of locoregional relapse (vaginal or pelvic recurrence, or both) were 5.1% (2.8–9.6) for VBT and 2.1% (0.8–5.8) for EBRT (HR 2.08, 0.71–6.09; p=0.17). 1.5% (0.5-4.5) versus 0.5% (0.1-3.4) of patients presented with isolated pelvic recurrence (HR 3.10, 0.32–29.9; p=0.30), and rates of distant metastases were similar (8.3% [5.1–13.4] vs 5.7% [3.3–9.9]; HR 1.32, 0.63–2.74; p=0.46). We recorded no differences in overall (84.8% [95% CI 79.3–90.3] vs 79.6% [71.2–88.0]; HR 1.17, 0.69–1.98; p=0.57) or disease-free survival (82.7% [76.9–88.6] vs 78.1% [69.7–86.5]; HR 1.09, 0.66–1.78; p=0.74). Rates of acute grade 1–2 gastrointestinal toxicity were significantly lower in the VBT group than in the EBRT group at completion of radiotherapy (12.6% [27/215] vs 53.8% [112/208]).</p> <p>See more outcome details in Creutzberg et al., 2000 and Nout et al., 2010.</p>